Syringes containing the Pfizer-BioNTech COVID-19 vaccine sit in a tray in a vaccination room at St. Joseph Hospital in Orange, Calif., Thursday, Jan. 7, 2021. (AP Photo/Jae C. Hong)
By Lauran Neergaard
New research suggests that Pfizer’s COVID-19 vaccine can protect against a mutation found in two easier-to-spread variants of the coronavirus that erupted in Britain and South Africa.
Those variants are causing global concern. They carry multiple mutations but share one in common that's believed to be the reason they are more contagious. Called N501Y, it is a slight alteration on one spot of the spike protein that coats the virus.
Most of the vaccines being rolled out around the world train the body to recognize that spike protein and fight it. Pfizer teamed with researchers from the University of Texas Medical Branch in Galveston for laboratory tests to see if the mutation affected its vaccine's ability to do so.
They used blood samples from 20 people who received the vaccine, made by Pfizer and its German partner BioNTech, during a large study of the shots. Antibodies from those vaccine recipients successfully fended off the virus in lab dishes, according to the study posted late Thursday on an online site for researchers.
The study is preliminary and has not yet been reviewed by experts, a key step for medical research.
But “it was a very reassuring finding that at least this mutation, which was one of the ones people are most concerned about, does not seem to be a problem” for the vaccine, said Pfizer chief scientific officer Dr. Philip Dormitzer.
A similar vaccine by Moderna is being rolled out in the U.S. and Europe, and on Friday was cleared in Britain. Moderna is doing similar testing to tell if its shot also works against the variants, as are makers of other types of COVID-19 vaccines.
But Dr. Anthony Fauci, the top U.S. infectious disease expert, recently told The Associated Press that vaccines are designed to recognize multiple parts of the spike protein, making it unlikely a single mutation could be enough to block them. Still, testing is needed to be sure.
Viruses constantly undergo minor changes as they spread from person to person. Scientists have used these slight modifications to track how the coronavirus has moved around the globe since it was first detected in China about a year ago.
British scientists have said the variant found in the U.K. – which has become the dominant type in parts of England -- still seemed to be susceptible to vaccines. That mutant has now been found in the U.S. and numerous other countries.
But the variant first discovered in South Africa has an additional mutation that has scientists on edge, one named E484K.
The Pfizer study found that the vaccine appeared to work against 15 additional possible virus mutations, but E484K wasn’t among those tested. Dormitzer said it is next on the list.
If the virus eventually mutates enough that the vaccine needs adjusting – much like flu shots are adjusted most years – that tweaking the recipe wouldn’t be difficult for his company's shot and similar ones. Both the Pfizer-BioNTech and Moderna vaccines are made with a piece of the virus genetic code, simple to switch, although it’s not clear what kind of additional testing regulators would require to make such a change.
Dormitzer said this was only the beginning “of ongoing monitoring of virus changes to see if any of them might impact on vaccine coverage.”
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
On this episode of Cheddar Innovates: Founder of Unlimited Tomorrow breaks down how he is creating completely 3D printed prosthetics to make them more affordable, customizable, and accessible; Chief Technology Officer of Zebra Technologies explains what the future of collaboration between robots and humans may look like; A look at Curiosity Stream's 'Mystery of the Roman Skulls.'
Each year about 5,000 people are diagnosed with ALS. This is such an important conversation. A disease that can weaken a patient's muscles and impact physical function. However, one research company says that could all change soon. Coya Therapeutics has developed a way to isolate a patient problematic T-cells in order to help ultimately slow the decline of not just ALS, but potentially Alzheimer's and other neurodegenerative diseases as well. Founder and Chief Executive Officer at Coya Therapeutics, Dr. Howard Berman, joined Cheddar to discuss more.
In the fight against climate change, much of the conversation revolves around reducing greenhouse gases like carbon dioxide or methane - and attempting to raise oxygen levels. But there's another gas - hydrogen - that could play a big role in the fight for the climate. Marco Alvera, CEO of Italian energy infrastructure company Snam and author of the book, 'The Hydrogen Revolution,' joined Cheddar Climate to explain the role hydrogen plays in helping achieve a net-zero future.
Americans looking to purchase at-home COVID-19 tests will now have to shell out a bit more money after an agreement expired between the White House and companies to sell the tests at cost. The price of Abbot's BinaxNow test kit from October to December was $14 apiece; on Tuesday, Walmart's website listed the test for $19.88, and Kroger listed the tests for $23.99. Carbon Health Regional Clinical Director Dr. Bayo Curry-Winchell joined Cheddar News' Closing Bell to discuss the impact higher prices will have as the nation experiences another surge in cases.
As millions of kids go back to school, districts across the country are determined to keep class in person, despite a surge in COVID cases. In New York City, Mayor Eric Adams has vowed to keep the nation's largest school system open amid Omicron, citing the disastrous effect of remote learning on students. Oswald Feliz, NYC council member who sits on the health and education committee, joined Cheddar to discuss the city's plan to combat the recent surge and keep kids in school.
Schools across the country are determined to keep class in session, despite the rapidly-spreading Omicron variant. While many parents prefer in-person learning, they also worry whether the current public health guidelines will be enough to protect their kids. Erin Richards, national education reporter for USA Today, joined Cheddar to discuss how are schools are preparing for the surge to avoid another round of remote learning.
With the annual CES convention underway amid COVID, HP unveiled rolled out a number of new products virtually this year, including new gaming PCs and 4K display monitors. But as industries look toward a greener future, HP is working with the climate crisis in mind. James McCall, chief sustainability officer at HP, joined Cheddar's Kristen Scholer to discuss the company's climate goals, which includes reducing its carbon footprint to net-zero by 2040. He admitted that reaching the ambitious goal will be difficult because much of the company's emissions totals come from third parties. "A large part of our footprint is outside of HP's direct control. A lot of it comes either from our incoming supply chain, the materials, our manufacturing process, or about 30 to 40 percent of it comes from our consumer-use base," McCall told Cheddar.
Pfizer and BioNTech are working to develop an mRNA-based shingles vaccine following the success of the COVID-19 shot. This latest collaboration will mark the third time the pharmaceutical companies have worked together on a vaccine.
The potential collapse of the Thwaites glacier in Antarctica has been deemed a potential "doomsday event" — researchers and scientists say its melting and collapse could raise global sea levels by at least two feet, enough to destroy coastal communities around the world. One team of scientists is traveling to the Thwaites glacier to drill below in order to gauge current ocean temperatures and attempt to model possible outcomes. David Holland, professor at NYU and Principal Investigator for the International Thwaites Glacier Collaboration, joins Cheddar Climate to discuss the glacier's potential collapse, his team's research plan, and more.
As winter break wraps up and COVID-19 cases hit record levels, the majority of school districts are returning to in-person classes. While some public schools in large cities have shifted to remote learning for the beginning of the year, the schools that are reopening campuses are determined to avoid the academic, social, and logistical challenges that come with a virtual classroom. Cheddar News is joined by Keith Powers, NYC Council Member, to discuss.
